{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:01:36Z","timestamp":1783116096918,"version":"3.54.6"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12350-022-03171-6","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T04:02:44Z","timestamp":1673668964000},"page":"1543-1553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prednisone vs methotrexate in treatment na\u00efve cardiac sarcoidosis"],"prefix":"10.1016","volume":"30","author":[{"given":"Roeland","family":"Vis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth G.M.","family":"Keijsers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewoudt M.W.","family":"van de Garde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Akdim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco C.","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-022-03171-6_bib1","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis","volume":"11","author":"Birnie","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1007\/s12350-022-03171-6_bib2","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.jacc.2020.08.042","article-title":"Challenges in cardiac and pulmonary sarcoidosis: JACC State-of-the-Art review","volume":"76","author":"Trivieri","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-022-03171-6_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1007\/s12350-022-03171-6_bib4","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1253\/circj.CJ-19-0508","article-title":"JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis-digest version","volume":"83","author":"Terasaki","year":"2019","journal-title":"Circ J"},{"key":"10.1007\/s12350-022-03171-6_bib5","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/eurheartj\/ehi180","article-title":"Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis","volume":"26","author":"Ishimaru","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1007\/s12350-022-03171-6_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jacc.2013.09.022","article-title":"Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis","volume":"63","author":"Blankstein","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-022-03171-6_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/ehjci\/jex340","article-title":"Diagnostic accuracy and prognostic value of simultaneous hybrid 18 F-fluorodeoxyglucose positron emission tomography\/magnetic resonance imaging in cardiac sarcoidosis","volume":"19","author":"Wicks","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"10.1007\/s12350-022-03171-6_bib8","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s12350-018-01504-y","article-title":"The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis","volume":"27","author":"Flores","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-022-03171-6_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12350-016-0682-1","article-title":"The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis","volume":"24","author":"Lee","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-022-03171-6_bib10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12350-016-0490-7","article-title":"The response of FDG uptake to immunosuppressive treatment on FDG PET\/CT imaging for cardiac sarcoidosis","volume":"24","author":"Ahmadian","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-022-03171-6_bib11","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s00259-018-4001-8","article-title":"Prognostic role of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET\/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia","volume":"45","author":"Muser","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1007\/s12350-022-03171-6_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cardfail.2019.02.018","article-title":"Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis","volume":"25","author":"Ning","year":"2019","journal-title":"J Card Fail"},{"issue":"4","key":"10.1007\/s12350-022-03171-6_bib13","doi-asserted-by":"crossref","DOI":"10.1148\/ryct.2020190140","article-title":"Utility of FDG PET and cardiac MRI in diagnosis and monitoring of immunosuppressive treatment in cardiac sarcoidosis","volume":"2","author":"Coulden","year":"2020","journal-title":"Radiol Cardiothorac Imaging"},{"key":"10.1007\/s12350-022-03171-6_bib14","first-page":"1034","article-title":"Corticosteroid therapy for cardiac sarcoidosis: A systematic review","volume":"29","author":"Sadek","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1007\/s12350-022-03171-6_bib15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ahj.2019.10.003","article-title":"Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT)","volume":"220","author":"Birnie","year":"2020","journal-title":"Am Heart J"},{"key":"10.1007\/s12350-022-03171-6_bib16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/14799731211031935","article-title":"Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population","volume":"18","author":"Kahlmann","year":"2021","journal-title":"Chron Respir Dis"},{"key":"10.1007\/s12350-022-03171-6_bib17","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"key":"10.1007\/s12350-022-03171-6_bib18","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MCP.0000000000000410","article-title":"Cardiac sarcoidosis: challenges in clinical practice","volume":"23","author":"Bakker","year":"2017","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1007\/s12350-022-03171-6_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12350-020-02201-5","article-title":"Quantitative assessment of cardiac hypermetabolism and perfusion for diagnosis of cardiac sarcoidosis","volume":"29","author":"Miller","year":"2022","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"10.1007\/s12350-022-03171-6_bib20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13550-018-0447-8","article-title":"Which is the proper reference tissue for measuring the change in FDG PET metabolic volume of cardiac sarcoidosis before and after steroid therapy?","volume":"8","author":"Furuya","year":"2018","journal-title":"EJNMMI Res"},{"key":"10.1007\/s12350-022-03171-6_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010952","article-title":"Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis","volume":"8","author":"Rosenthal","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1007\/s12350-022-03171-6_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2169\/internalmedicine.53.0794","article-title":"Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions","volume":"53","author":"Nagai","year":"2014","journal-title":"Intern Med"},{"key":"10.1007\/s12350-022-03171-6_bib23","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/ejhf.1319","article-title":"Management and outcomes of cardiac sarcoidosis: A 20-year experience in two tertiary care centres","volume":"20","author":"Fussner","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1007\/s12350-022-03171-6_bib24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijcard.2018.11.131","article-title":"Treatment of cardiac sarcoidosis: A comparative study of steroids and steroids plus immunosuppressive drugs","volume":"276","author":"Ballul","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1007\/s12350-022-03171-6_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir Med"},{"issue":"6","key":"10.1007\/s12350-022-03171-6_bib26","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s12350-018-01541-7","article-title":"18F-FDG uptake of the right ventricle is an important predictor of histopathologic diagnosis by endomyocardial biopsy in patients with cardiac sarcoidosis","volume":"27","author":"Omote","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-022-03171-6_bib27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s12149-014-0860-7","article-title":"Right ventricular (18)F-FDG uptake is an important indicator for cardiac involvement in patients with suspected cardiac sarcoidosis","volume":"28","author":"Manabe","year":"2014","journal-title":"Ann Nucl Med"},{"key":"10.1007\/s12350-022-03171-6_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s12350-014-9901-9","article-title":"Quantitative interpretation of FDG PET\/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis","volume":"21","author":"Ahmadian","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-022-03171-6_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/clc.4960270409","article-title":"Ventricular tachyarrhythmia associated with cardiac sarcoidosis: Its mechanisms and outcome","volume":"27","author":"Furushima","year":"2004","journal-title":"Clin Cardiol"},{"key":"10.1007\/s12350-022-03171-6_bib30","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.hrthm.2007.06.006","article-title":"Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis","volume":"4","author":"Banba","year":"2007","journal-title":"Heart Rhythm"},{"key":"10.1007\/s12350-022-03171-6_bib31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCIMAGING.112.000289","article-title":"Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by 18F-fluorodoexyglucose positron emission tomography?","volume":"6","author":"McArdle","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"17","key":"10.1007\/s12350-022-03171-6_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021183","article-title":"Corticosteroid and immunosuppressant therapy for cardiac sarcoidosis: A systematic review","volume":"10","author":"Fazelpour","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-022-03171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12350-022-03171-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358124000539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358124000539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-022-03171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:15:15Z","timestamp":1761027315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358124000539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1071358124000539"],"URL":"https:\/\/doi.org\/10.1007\/s12350-022-03171-6","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prednisone vs methotrexate in treatment na\u00efve cardiac sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-022-03171-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}